Company:  FOAMIX PHARMACEUTICALS LT ...
Form Type:  8-K
Filing Date:  1/14/2020 
CIK:  0001606645 
Address:  2 HOLZMAN ST.
WEIZMANN SCIENCE PARK
 
City, State, Zip:  REHOVOT,  76704 
Telephone:  97289316233 
Fiscal Year:  12/31 
Description of Business
We are a late clinical-stage specialty pharmaceutical company focused on developing and commercializing our proprietary, innovative and differentiated topical drug candidates for dermatological therapy. Our lead product candidate, FMX101 (4% minocycline foam), is being developed for the treatment of moderate-to-severe acne and our second product candidate, FMX103 (1.5% minocycline foam), is being developed for the treatment of moderate-to-severe papulopustular rosacea. Both product candidates are novel topical foam formulations of the antibiotic minocycline and were developed using our Molecule Stabilizing Technology, a proprietary foam platform designed to optimize the topical delivery of minocycline, an active pharmaceutical ingredient, or API, that is currently available only in oral form despite its prevalent use in dermatology. We announced positive top-line results from both of our Phase III clinical trials for each of FMX101 and FMX103 in the second half of 2018.
Register and access this filing in:     
  FORM 8-K
    SECTION 7 REGULATION FD
      Item 7.01 Regulation FD Disclosure.
    SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS
      Item 9.01 Financial Statements and Exhibits.
    SIGNATURES
  EXHIBIT 99.1